glycopyrrolate has been researched along with Dyspnea in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, J; Compton, C; Czira, A; Dong, X; Duarte, M; Haeussler, K; Halpin, DMG; Ismaila, AS; Malmenäs, M; Nassim, M; Shen, Y; Tongbram, V; Vogelmeier, CF; Živković-Gojović, M | 1 |
| Attri, S; Ballal, S; Darken, P; de Nigris, E; Ferguson, GT; Holmgren, U; Siddiqui, MK; Singh, B | 1 |
| Denenberg, M; Donohue, JF; Hanania, NA; Kerwin, EM; Maes, A; O'Donnell, DE; Orevillo, C; Quinn, D; Reisner, C; Siddiqui, S; Tashkin, DP | 1 |
| Banerji, D; Fogel, R; Fucile, S; Kostikas, K; Mezzi, K; Shen, S; Tsiligianni, I | 1 |
| Aalamian-Mattheis, M; Castellani, W; Clemens, A; Gaga, M; Greulich, T; Kostikas, K; Lane, S; Marin, JM; Ninane, V; Nunez, X; Patalano, F; Vogelmeier, CF | 1 |
| Aalamian-Mattheis, M; Clemens, A; Fogel, R; Kostikas, K; Nunez, X; Pagano, VA; Patalano, F | 1 |
| Alagappan, VK; Banerji, D; Chen, H; D'Urzo, A; Decramer, M; Gallagher, N; Kulich, K; Mahler, DA; White, T; Worth, H | 1 |
| Bai, L; D'Andrea, P; Firth, R; Huang, Y; Humphries, M; Kho, P; Li, L; Sun, T; Wang, C; Wang, Q | 1 |
| Cazzola, M; Matera, MG; Rogliani, P | 1 |
| Cockle, SM; Huisman, EL; Ismaila, AS; Karabis, A; Punekar, YS | 1 |
| Centanni, S; Di Marco, F; Raccanelli, R; Radovanovic, D; Santus, P; Valenti, V | 1 |
| Ulrik, CS | 1 |
| D'Andrea, P; Eckert, JH; Feldman, G; Henley, M; LaForce, C; Patalano, F; Spangenthal, S | 1 |
5 review(s) available for glycopyrrolate and Dyspnea
| Article | Year |
|---|---|
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Dyspnea; Forced Expiratory Volume; Glycopyrrolate; Humans; Muscarinic Antagonists; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Salmeterol Xinafoate; Tiotropium Bromide; Treatment Outcome | 2022 |
Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Bayes Theorem; Bronchodilator Agents; Budesonide; Drug Combinations; Dyspnea; Female; Forced Expiratory Volume; Formoterol Fumarate; Fumarates; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Agonists; Muscarinic Antagonists; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Treatment Outcome | 2020 |
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Drug Combinations; Dyspnea; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones | 2015 |
Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.
Topics: Bronchodilator Agents; Drug Combinations; Drug Therapy, Combination; Dyspnea; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Tiotropium Bromide; Treatment Outcome | 2015 |
Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).
Topics: Administration, Inhalation; Bronchodilator Agents; Dyspnea; Exercise Tolerance; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2015 |
8 trial(s) available for glycopyrrolate and Dyspnea
| Article | Year |
|---|---|
Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Drug Therapy, Combination; Drug Tolerance; Dyspnea; Female; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Smoking; Tiotropium Bromide; Treatment Outcome | 2017 |
Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program.
Topics: Aged; Bronchodilator Agents; Drug Combinations; Dyspnea; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Glycopyrrolate; Health Status; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Sex Factors; Tiotropium Bromide; Vital Capacity | 2017 |
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Bronchodilator Agents; Disease Progression; Drug Combinations; Drug Substitution; Dyspnea; Europe; Female; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Patient Safety; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Recovery of Function; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study.
Topics: Aged; Bronchodilator Agents; Drug Combinations; Dyspnea; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Patient Reported Outcome Measures; Prognosis; Pulmonary Disease, Chronic Obstructive; Quinolones; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2018 |
Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study.
Topics: Adult; Aged; Area Under Curve; Bronchodilator Agents; Cross-Over Studies; Drug Combinations; Dyspnea; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Powders; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Spirometry; Tiotropium Bromide; Treatment Outcome | 2014 |
Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.
Topics: Adult; Aged; Asian People; Bronchodilator Agents; China; Double-Blind Method; Drug Administration Schedule; Dyspnea; Female; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; India; Lung; Male; Middle Aged; Muscarinic Antagonists; Philippines; Pulmonary Disease, Chronic Obstructive; Recovery of Function; Republic of Korea; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity | 2015 |
Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study.
Topics: Aged; Aged, 80 and over; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Dyspnea; Endpoint Determination; Female; Glycopyrrolate; Humans; Lung; Male; Middle Aged; Plethysmography; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Residual Volume; Respiratory Function Tests; Tropanes | 2015 |
Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Dyspnea; Female; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; United States | 2016 |